Skip to main content
. Author manuscript; available in PMC: 2020 Mar 1.
Published in final edited form as: Am J Transplant. 2018 Sep 24;19(3):674–685. doi: 10.1111/ajt.15087

Figure 8. Impaired efficacy of donor ECDI-SP in Mertk−/− recipients is rescued by IFN-α blockade.

Figure 8.

(A) Groups of Mertk−/− or Mertk+/+ recipients were treated with BALB/c ECDI-SP with or without anti-IFNaR1 (or isotype antibody) as indicated, and transplanted with a BALB/c islet allograft. Graft survival was determined as described in Methods. (B) Groups of Mertk−/− or Mertk+/+ recipients were treated with BALB/c ECDI-SP and/or anti-IFNaR1 (or isotype antibody) as indicated, and transplanted with a BALB/c heart allograft. Graft survival was determined as described in Methods. (C) Groups of Mertk−/− or Mertk+/+ recipients were treated with BALB/c ECDI-SP and/or rIFN-α as indicated, and transplanted with a BALB/c heart allograft. Graft survival was similarly determined. (A-C) Statistical significance was determined using Log-rank (Mantel-Cox) test. ***P ≤ 0.001.